ライフサイエンスコーパス: nonresponsiveness

1 s in the form of a postactivational phase of nonresponsiveness.

2 appeared to be limited by induction of IL-7 nonresponsiveness.

3 of IL-17F greater than 200 pg/mL may predict nonresponsiveness.

4 en-transgenic RBCs also demonstrated induced nonresponsiveness.

5 o determine if oral bioavailability mediates nonresponsiveness.

6 g molecule equol was consistent with overall nonresponsiveness.

7 cancer is one of the major factors of tumor nonresponsiveness.

8 result in CD8 T-cell deletion or functional nonresponsiveness.

9 o define sustained periods of donor-specific nonresponsiveness.

10 n Ags typically induces Ag-specific systemic nonresponsiveness.

11 dy responses may play in the observed immune nonresponsiveness.

12 f the transgene has not resulted in complete nonresponsiveness.

13 of BCR-ligand recognition can lead to B cell nonresponsiveness, activation, or inhibition.

14 This activation-induced nonresponsiveness (AINR) is not simply a consequence of

15 ollowing restimulation, they rapidly develop nonresponsiveness and exhibit elevated activation-induce

16 y lead to an IL-10-induced form of anergy or nonresponsiveness and generation of the recently charact

17 donor animals could induce a state of T-cell nonresponsiveness and prevent the development of graft-v

18 PCs from RA patients displayed growth factor nonresponsiveness and sluggish cell cycle progression; m

19 might transition between responsiveness and nonresponsiveness, and between different modes of gradie

20 s associated with reversal of tumor-mediated nonresponsiveness/anergy as well as establishment of lon

21 elp at priming results in long-term antibody nonresponsiveness, antibody responses can be induced by

22 the mechanisms of immune responsiveness, or nonresponsiveness, are governed by the migration and loc

23 In addition, parasite-induced nonresponsiveness, as measured by TNF-alpha production,

24 In conclusion, T-cell nonresponsiveness because of active suppression mediated

25 involvement of the HLA-DRB1 gene in vaccine nonresponsiveness but not altered susceptibility to vira

26 However, the ability to overcome immunologic nonresponsiveness by targeting poorly immunogenic Ags to

27 man trials suggest that tolerance (sustained nonresponsiveness) can be re-established in a subset of

28 Anergy is a state of T-cell nonresponsiveness characterized by downregulated IL-2 pr

29 Elucidation of the mechanisms of nonresponsiveness (clonal exhaustion-deletion and immune

30 achieved a transient state of immunological nonresponsiveness correlated with higher titers of the I

31 ive potential per Tg+ cell demonstrates that nonresponsiveness due to feeding Ag results in the induc

32 We conclude that immunological pathways of nonresponsiveness follow different patterns depending bo

33 o an active induction of an antigen-specific nonresponsiveness (i.e. immunological tolerance).

34 ormally results in local and systemic immune nonresponsiveness in a process termed oral tolerance.

35 in T cells is sufficient to induce cytokine nonresponsiveness in both a T cell clone and naive prima

36 ers, indicating a prior state of immunologic nonresponsiveness in the context of AAV gene therapy.

37 hematopoietic chimeras showed donor-specific nonresponsiveness in the mixed lymphocyte reaction, lack

38 gen presentation by epithelial cells induced nonresponsiveness in the T cell clones.

39 ability of CTLA4Ig to lead to long-standing nonresponsiveness in this model depends on the nature (i

40 rus-mediated upregulation induced a state of nonresponsiveness in uninfected HIV-specific T cells.

41 asystole (after approximately 30 minutes of nonresponsiveness) in 1 case.

42 mage and repair interspersed with periods of nonresponsiveness indicative of a refractory period.

43 T-cell nonresponsiveness is a critical factor in immune escape

44 In this case, nonresponsiveness is accompanied by the induction of p21

45 In this study, we demonstrate that cytokine nonresponsiveness is accompanied by the induction of the

46 rrent study, we aimed to investigate whether nonresponsiveness is an Ag/vaccine-specific phenomenon a

47 Low responsiveness/nonresponsiveness is characterized by an insufficient im

48 ellular and molecular basis for the observed nonresponsiveness is not fully understood.

49 ve continued proliferation of AINR cells and nonresponsiveness is reversed within 1-2 days so that Ag

50 Donor-specific nonresponsiveness is transient in most patients, and ser

51 However, nonresponsiveness is widely recognized and is related to

52 a suggest that anti-CD3 mAb-induced cytokine nonresponsiveness may be a consequence of hyperactivatio

53 607 T/T/APOE varepsilon3 was associated with nonresponsiveness (mean +/- SEM: +0.09 +/- 0.08 mmol/L,

54 (P2 and P3) are sufficient to induce immune nonresponsiveness (median survival time >237 days) to ca

55 flora or food Ags, it must induce a state of nonresponsiveness (mucosal tolerance).

56 ct of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet

57 This nonresponsiveness occurs because of a lack of expression

58 sents a promising approach to overcoming the nonresponsiveness of certain cancer patients to this sel

59 To gain more insight into the purported nonresponsiveness of human liver cells to peroxisome vol

60 The nonresponsiveness of MV-infected human lymphocytes to mi

61 roteolytic degradation may contribute to the nonresponsiveness of patients with IBD to anti-TNF agent

62 fine the structural basis for the allosteric nonresponsiveness of sCPS and thereby provide insight in

63 Immune tolerance is defined as nonresponsiveness of the adaptive immune system to antig

64 f patients at high or low risk for treatment nonresponsiveness or death, and they may provide opportu

65 Identification of antiplatelet nonresponsiveness or hyporesponsiveness is highly test s

66 a and TGFbeta signaling, such that tamoxifen nonresponsiveness or resistance in breast cancer might i

67 The ability to trigger a state of nonresponsiveness represents a unique MHC-independent me

68 is the induction of T cell anergy, a form of nonresponsiveness resulting from incomplete T cell activ

69 ice congenic for slow acetylation and/or Ahr-nonresponsiveness; some groups were pretreated with beta

70 targeting to CD64 can overcome immunological nonresponsiveness to a weak immunogen.

71 with proinflammatory cytokine increases and nonresponsiveness to antiinfluenza vaccine in the elderl

72 CL10 may be a predictor of responsiveness or nonresponsiveness to antiviral therapy with pegylated in

73 he MAP kinases, ERKs 1 and 2, and consequent nonresponsiveness to AP-1 activation.

74 ti-CD40L monoclonal antibodies suggests that nonresponsiveness to cell membrane-bound antigen (e.g.,

75 hypermethylation is associated with clinical nonresponsiveness to chemotherapy in colorectal cancer.

76 Ticagrelor therapy overcomes nonresponsiveness to clopidogrel, and its antiplatelet e

77 abolites could prevent development of T cell nonresponsiveness to cognate Ag.

78 Importantly, GC T cell nonresponsiveness to CXCL12 correlated with high ex vivo

79 f oral tolerance in sustaining immunological nonresponsiveness to food Ags, our current understanding

80 me that high IDO activity is associated with nonresponsiveness to food allergens despite allergen sen

81 o induce and maintain Mphi cytokine-specific nonresponsiveness to LPS.

82 ly, CD8+ T cells from tolerant mice transfer nonresponsiveness to naive syngeneic recipients.

83 em to gain an insight into the mechanisms of nonresponsiveness to PSA, ultimately leading to strategi

84 lls lowered ped/pea-15 expression and caused nonresponsiveness to rosiglitazone, although c-jun overe

85 rgy, as CLL cells exhibit variable levels of nonresponsiveness to surface IgM stimulation that is rev

86 opment of a vascular crisis characterized by nonresponsiveness to sympathetic vasoconstrictor agents

87 g genes by miR-155 likely contributes to the nonresponsiveness to TGFbeta during SIV infection and ma

88 ositive CD8(+) T cells demonstrated profound nonresponsiveness to the specific peptide, whereas nitro

89 serum of people with RRMS is associated with nonresponsiveness to therapy with IFN-beta.

90 s have been offered to explain this apparent nonresponsiveness to warming, including the influence of

91 ings of these drugs include the induction of nonresponsiveness upon repeated use and the expansion of

92 mmed for signal- and stage-specific "nuclear nonresponsiveness" upon encounter with self-Ags.

93 Concurrent with the induction of nonresponsiveness, virus-specific cells that retained fu

94 The rate of aspirin nonresponsiveness was 15.8%, 8.1%, and 52.8% for plain a

95 Mucosal, but not peripheral, nonresponsiveness was abrogated by the inclusion of a ne

96 Nonresponsiveness was defined as <10% absolute change in

97 Aspirin nonresponsiveness was defined as a level of residual ser

98 Nonresponsiveness was defined as failure to mount an HAI

99 Nonresponsiveness was lower after 600 mg compared to the

100 pecific peripheral cell-mediated and humoral nonresponsiveness was maintained in both Stat 4-/- and S

101 This donor antigen-linked nonresponsiveness was observed in four other patients wh

102 This nonresponsiveness was reversed by an anti-TGF-beta1-neut

103 nical isolates excluded the possibility that nonresponsiveness was the result of mutation(s) in L1.

104 vironment in the induction of orally induced nonresponsiveness, we attempted to induce tolerance to O

105 HLA-DR subtypes associated with hepatitis B nonresponsiveness were overrepresented in this group, an

106 al MHC class II molecules that induce T cell nonresponsiveness with Ag presentation.

107 plain aspirin and PL2200, this high rate of nonresponsiveness with EC aspirin was associated with lo